Search filters

List of works by Courtney D DiNardo

A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia

scientific article published on 25 February 2020

A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis

scientific article published on 11 January 2019

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis

scientific article published on 05 September 2018

A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia.

scientific article published on 14 June 2017

A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia

scientific article published on 18 July 2017

A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents

scientific article published on 15 November 2018

A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.

scientific article

A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia

scientific article

A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia

scientific article

Acute myeloid leukemia with t(10;11): a pathological entity with distinct clinical presentation

scientific article published on 21 June 2014

Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia

scientific article published on 11 October 2018

Advances in patient care through increasingly individualized therapy

scientific article published on 01 February 2019

Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia.

scientific article published on 20 March 2018

BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells

scientific article published on 28 September 2016

Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome

scientific article

Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation

scientific article

Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias

scientific article published on 27 September 2016

Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach

scientific article

Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype

scientific article published on 04 May 2020

Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML

scientific article

Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial

scientific article published on 13 August 2018

Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia

scientific article published on 27 April 2018

Clinical Experience of Venetoclax Combinations for Relapsed/Refractory Myeloid Malignancies

scientific article published in October 2017

Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia

scientific article published on 26 July 2017

Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia

scientific article published on 06 November 2020

Clinical Outcomes in Adult Patients with Aplastic Anemia- a single institution experience

scientific article published on 29 August 2017

Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations

scientific article published on 29 October 2020

Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis

scientific article

Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

scientific article

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents

scientific article published on 09 February 2016

Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1

scientific article published on 01 April 2020

Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients

scientific article published on 24 November 2015

Clonal Evolution and Treatment Outcomes in Hematopoietic Neoplasms Arising in Patients with Germline RUNX1 mutations

scientific article published on 17 August 2020

Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

scientific article published on 21 October 2020

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study

scientific article published on 29 September 2015

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study

scientific article published on 01 December 2018

DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease

scientific article published on 07 May 2019

Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes

scientific article published on 19 October 2015

Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia

scientific article published on 7 September 2016

Dorsal column myelopathy after intrathecal chemotherapy for leukemia

scientific article published on 22 November 2016

Early detection of transformation to BPDCN in a patient with MDS

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

scientific article

Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study

scientific article published on 08 November 2018

Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia

scientific article published on 09 April 2019

Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.

scientific article

Hematopoiesis under telomere attrition at the single-cell resolution

scientific article published on 25 November 2021

How I treat acute myeloid leukemia in the era of new drugs

scientific article published on 01 January 2020

Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial

scientific article published on 01 July 2020

Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study

scientific article published on 07 August 2019

Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin

scientific article published on 30 April 2020

Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents

scientific article published on 11 January 2017

Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes

scientific article

Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia

scientific article published on 04 May 2020

Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels

scientific article published on 06 April 2018

Incidence of Tumor Lysis Syndrome in Patients with Acute Myeloid Leukemia Undergoing Low-Intensity Induction with Venetoclax

scientific article published on 01 December 2020

Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study

scientific article published on 15 January 2018

Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes

scientific article published in Nature Communications

Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts

scientific article published on 29 April 2019

Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)

scientific article

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia

scientific article published on 01 February 2020

Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia

scientific article published on 27 February 2019

Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival

scientific article published on 6 June 2015

Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents

scientific article published on 4 February 2014

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia

scientific article published on 10 May 2021

Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab

scientific article published on 21 December 2016

Low frequency of H3.3 mutations and upregulated DAXX expression in MDS ⬇️

scientific article published on May 9, 2013

Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML

scientific article published on 01 May 2020

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

scientific article published on 01 March 2020

More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia.

scientific article

Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

scientific article published on 29 October 2020

Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable

scientific article published on 21 September 2018

New directions for emerging therapies in acute myeloid leukemia: the next chapter

scientific article published on 30 October 2020

Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy

scientific article published on 28 February 2020

Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia

scientific article published on 17 January 2018

Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML

scientific article published on 08 October 2020

Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia

scientific article published on 22 September 2016

Persistent mutations in remission can predict relapse in patients with acute myeloid leukemia

scholarly article by Chi Young Ok et al published February 2019 in Haematologica

Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia

scientific article published on 22 January 2019

Phase 2 Study of Hyper-CMAD with Liposomal Vincristine for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia

scientific article published on 14 March 2020

Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia

scientific article published on 20 December 2018

Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality

scientific article published on 16 June 2020

Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors

scientific article published on 03 March 2020

Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study

scientific article published on 02 December 2016

Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors

scientific article

Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib

scientific article published on 24 June 2019

Publisher Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

scientific article published on 19 November 2020

RUNX3 promoter hypermethylation is frequent in leukaemia cell lines and associated with acute myeloid leukaemia inv(16) subtype

scientific article published on 22 January 2015

Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.

scientific article published on 12 April 2018

Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial

scientific article

SOHO State of the Art Update and Next Questions: IDH Therapeutic Targeting in AML

scientific article published on 21 October 2018

Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia

scientific article published on 18 August 2017

Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results

scientific article published on 30 July 2020

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

scientific article published on 12 January 2018

Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study

scientific article published on 22 December 2014

Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia

scientific article published on 16 July 2019

Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation

scientific article published on 29 August 2019

Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells

scholarly article by Warren Fiskus et al published 15 January 2019 in Blood Cancer Journal

Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years

scientific article published on 05 August 2020

TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes

scientific article published on 26 July 2016

The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia

scientific article published on 19 June 2020

The LEukemia Artificial Intelligence Program (LEAP) in Chronic Myeloid Leukemia in Chronic Phase: A Model to Improve Patient Outcomes

scientific article published on 12 November 2020

Time to blur the blast boundaries

scientific article published in 2022

Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis

scientific article published on 19 July 2017

Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial

scientific article published on 10 December 2018

Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience

scholarly article by Kamal Chamoun et al published 3 January 2019 in Journal of Hematology & Oncology

Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia

scientific article published on 31 May 2019

Validation of a clinical assay of multi-locus DNA methylation for prognosis of newly diagnosed AML.

scientific article

Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes

scientific article published on 06 December 2018

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

scholarly article by Courtney D DiNardo et al published 25 October 2018 in Blood

Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy

scientific article published on 23 October 2019

Venetoclax with Decitabine Versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality

scientific article published on 02 December 2020

Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a Phase 1b study

scientific article published on 29 October 2020

Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome

scientific article published on 20 July 2017

mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy

Paulina is supported by:

About Paulina

Help